Emergence of Oligoclonal Bands in Association with the use of Chemotherapy and Hematopoietic Stem Cell Transplantation

Paul, Chandramallika; Chakraborty, Sibani; Chakraborty, Subhosmito

doi:10.1007/s12291-021-00983-0

Cited by 2 publications

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…M‐P immune reconstitution was more common in patients who underwent ASCT and in those who achieved CR. As reported in previous studies, 9,11,20 a preponderance of IgG isotype monoclonal immunoglobulin was observed in our study. It seems that, in the context of ASCT for MM, the emergence of these oligoclonal immunoglobulins can be a consequence of strong immune reconstitution 14 …”

Section: Discussionsupporting

confidence: 91%

“…Although initially described as transient, there is growing evidence that this humoral response can be maintained for some years 3,5,9 . The incidence of an M‐protein immune reconstitution has a wide range in the literature, from single digits to 73% 5,8,10–12 . It is said to be due to the recovery of B‐cell function after myeloablative therapy and to represent durable immune reconstitution 3–5 .…”

Section: Introductionmentioning

confidence: 99%

“…3,5,9 The incidence of an M-protein immune reconstitution has a wide range in the literature, from single digits to 73%. 5,8,[10][11][12] It is said to be due to the recovery of B-cell function after myeloablative therapy and to represent durable immune reconstitution. [3][4][5] Optimal treatment for patients with MM under 65 years of age includes induction therapy followed by highdose melphalan (HDM) with autologous peripheral blood stem cell transplant (ASCT).…”

mentioning

confidence: 99%

See 2 more Smart Citations

Early M‐protein immune reconstitution after autologous haematopoietic stem cell transplantation is a good prognostic marker for patients with high‐risk cytogenetic multiple myeloma

Zhu,

Liu,

et al. 2024

Br J Haematol

View full text Add to dashboard Cite

SummaryThe presence of transient abnormal protein banding (M‐protein immune reconstitution) in serum immunofixation electrophoresis after autologous haematopoietic stem cell transplantation in patients with multiple myeloma has been reported. The purpose of this study was to investigate the impact of post‐transplant M‐protein immune reconstitution on the prognosis of patients with multiple myeloma. M‐protein immune reconstitution was observed in 25.9% (75/290) of patients. The CR rate and MRD negativity were higher in the M‐protein immune reconstitution group (85.3% vs. 69.3%, p = 0.013, 81.9% vs. 66.5%, p = 0.014). Although there were no significant differences between the groups, the overall median survival time was longer in the M‐protein immune reconstruction group (80 vs. 72 m, p = 0.076; not reached vs. 105 m, p = 0.312). Among patients in the cytogenetic high‐risk group, the occurrence of M‐protein immune reconstitution predicted better PFS and OS (80 vs. 31 m, p = 0.010; not reached vs. 91 m, p = 0.026). Additionally, in revised‐International Staging System stage III patients, PFS and OS were better in those who achieved M‐protein immune reconstitution (80 vs. 20 m, p = 0.025; 57 vs. 32 m, p = 0.103). The better prognosis of M‐protein immune reconstitution patients may be associated with the acquisition of a deeper response. In high‐risk patients, early acquisition of M‐protein immune reconstitution may suggest a better prognosis.

show abstract

Section: Discussionsupporting

confidence: 91%